Or they was never gone…
And they’re hijacking again public health, environmentalism, technology and science to shut the useless eater from the map!!!
Dealing with The Devil:
The Triumph and Tragedy
of IBM’s Business with the Third Reich
IBM and the Holocaust
The Holocaust was the state-sponsored persecution and mass murder of millions of European Jews, Romani people, the intellectually disabled, political dissidents and homosexuals by the German Nazi regime between 1933 and 1945. The word “holocaust,” from the Greek words “holos” (whole) and “kaustos” (burned), was historically used to describe a sacrificial offering burned on an altar.
After years of Nazi rule in Germany, dictator Adolf Hitler’s “Final Solution”—now known as the Holocaust—came to fruition during World War II, with mass killing centers in concentration camps. About six million Jews and some five million others, targeted for racial, political, ideological and behavioral reasons, died in the Holocaust—more than one million of those who perished were children.
Since June 1941, experiments with mass killing methods had been ongoing at the concentration camp of Auschwitz, near Krakow, Poland. That August, 500 officials gassed 500 Soviet POWs to death with the pesticide Zyklon-B. The SS soon placed a huge order for the gas with a German pest-control firm, an ominous indicator of the coming Holocaust.
INNOVATION AND INVENTION drive the world forward and thrive off a free market that rewards individuals and companies that can tap unto supply and demand. During tragedy, especially wartime, this can take a dark turn when the triumph of invention and profit is gained from human tragedy. International Business Machines Corporation (IBN), saw warfare as an opportunity to capitalize off of both sides. As the Nazis rose to power, they needed the machinery to identify, organize, and number the Jewish population. IBM sought this as a favorable position for corporate gain and began leasing tabulating machinery to the Nazi regime. IBM’s endorsement of the Third Reich yielded capital gain at the cost of millions
of lives. This advanced technology, which enabled IBM’s profit from the Holocaust, set the scene for the company’s dominance throughout the 20th century while ultimately enabling a calculated genocide.The Tattoos with the numbers was an IBM Code!
Holocaust Death Camps
Beginning in late 1941, the Germans began mass transports from the ghettoes in Poland to the concentration camps, starting with those people viewed as the least useful: the sick, old and weak and the very young.
The first mass gassings began at the camp of Belzec, near Lublin, on March 17, 1942. Five more mass killing centers were built at camps in occupied Poland, including Chelmno, Sobibor, Treblinka, Majdanek and the largest of all, Auschwitz.
From 1942 to 1945, Jews were deported to the camps from all over Europe, including German-controlled territory as well as those countries allied with Germany. The heaviest deportations took place during the summer and fall of 1942, when more than 300,000 people were deported from the Warsaw ghetto alone.
Wikimedia Commons
At Auschwitz alone, more than 2 million people were murdered in a process resembling a large-scale industrial operation. A large population of Jewish and non-Jewish inmates worked in the labor camp there; though only Jews were gassed, thousands of others died of starvation or disease.
In 1943, eugenics advocate Josef Mengele arrived in Auschwitz to begin his infamous experiments on Jewish prisoners. His special area of focus was conducting medical experiments on twins, injecting them with everything from petrol to chloroform under the guise of giving them medical treatment. His actions earned him the nickname “the Angel of Death.”
Harry Murphy, St. Peter 3 School, Philadelphia, PA
Junior Division Historical Paper, National History Day 2019 Competition
How IBM Technology Jump Started the Holocaust
By Edwin Black
Published June 16, 2011
When Hitler rose to power, German intellect descended into madness. The Nazi movement was not merely a throng of hooligans pelting windows and screaming slogans. Guiding the Brown Shirts and exhorting the masses was an elite coterie of pseudo-scientists, corrupted professionals, and profit-blinded industrialists. Nazi jurists, medical doctors, and a clique of scientists — each with their prestigious academic credentials — found ways to pervert their science and higher calling to advance the cause of Aryan domination and racial persecution.
That story begins two months after Hitler became Germany’s chancellor in January 1933, at which point he established the first concentration camp for political prisoners. By the next month, 60,000 were imprisoned.
This is when the German government revealed its plan to hold a long-delayed national census. This type of business was IBM’s bread and butter and Dehomag, the German subsidiary, was first in line for the job. IBM thus boosted its investment in Dehomag almost 20-fold, with that money largely going toward building IBM’s first factory in Germany.
According to Black, the Nazi government then used the equipment and training IBM had invested in the German market to identify so-called undesirables. After the Nazis completed the census, they discovered that two million people of Jewish descent lived in Germany — not half a million, as they’d previously thought.
As the Nazis began taking action against them, public calls for the U.S.’ economic boycott of Germany commenced. However, according to Black at least, IBM ignored the outcry. In fact, the person in charge of Dehomag — Willy Heidinger — was an outright Nazi supporter, thus making Dehomag friendly to the regime. Black contends that as it became increasingly difficult to conduct business in Nazi Germany, Watson and Heidinger made a secret deal to use Heidinger and Dehomag’s clout with the Nazis to supply punched-card technology to IBM customers in territories that had recently come under Nazi control.
Deutsches MuseumMachines like this — the Dehomag Tabulator D11, made by an IBM subsidiary — were used to carry out the Holocaust.
Bolstering this theory, in the 2012 reissue Black presents a letter dated 1941 from IBM that directed a Dutch subsidiary to work with Dehomag — years after business with Germany was supposed to have ceased. Furthermore, according to Black’s 2012 evidence, Watson took a one percent commission on all profits made in business with the Nazis, and had to personally approve all expenditures on said business, such as bomb-fortifying Dehomag installations.
The most damning of Black’s new evidence, however, is likely two U.S. government memos. The first is a Justice Department memo written during a federal investigation into IBM’s collaboration with the Nazis. In that memo, Economic Warfare Section Chief Investigator Howard J. Carter wrote, “What Hitler has done to us through his economic warfare, one of our own American corporations has also done . . . Hence IBM is in a class with the Nazis . . . The entire world citizenry is hampered by an international monster.”
The second memo, dated four days before Pearl Harbor, comes from the State Department. IBM’s top attorney, Harrison Chauncey, had visited the State Department to discuss IBM’s involvement with the Nazis. The memo read that Chauncey expressed anxiety “that his company may some day be blamed for cooperating with the Germans.”
Given the case Black makes against IBM, his book has faced rather critical reception. When it first came out, for example, Bloomberg Businessweek and The New York Times skewered it, citing faulty research methodology and bombastic hyperbole.
In response, Black simply directed ATI to a page on his website that lists the various media outlets that have criticized his book but later published retractions. Elsewhere Black has publicly stated that criticism comes from dislike of his person, not what appears in his work.
Indeed, as Mic puts it:
“Despite Black’s firebrand ethos, his meticulous research has uncovered tens of thousands of documents, culled together from across Europe, that carefully show how IBM didn’t just provide technology to Hitler’s Germany — it helped implement and maintain it for whatever purposes the Nazis required.”
In fact, Newsweek, The Sunday Times, and The Washington Post all gave Black’s book positive reviews.
Whatever your take on the book, it’s clear that Black indeed conducted copious research through scores of documents that the rest of the world has simply ignored. Even New York University and the University of Stuttgart, the two institutions to which IBM sent their World War II-era documents, haven’t given that evidence a close look.
When ATI reached out to both institutions and asked to be put in touch with an expert who had studied the files, Stuggart responded by saying that the files likely didn’t exist in their archives, while NYU said that they’ve acted only as a repository for the documents — and that much of the collection relates to IBM’s subsequent efforts to regain shareholder control of its German subsidiaries and machines after Allied victory.
As NYU states, we shouldn’t forget that even after the Holocaust shocked the world, IBM sought to regain control of its interests in Germany. Clearly, no matter what the circumstances, this company always had its eye on the prize, and knew precisely what it was doing. That’s why it’s hard to believe that, when it comes to doing business with the Nazis, IBM wasn’t aware of what it was doing in every sense.
And in the early 2000s, some people wanted to call IBM on it. In 2001 and 2004, victims of Nazi persecution filed two class-action lawsuits against IBM. In 2006, a Swiss court deemed the statute of limitations to have expired and dismissed the 2004 case, while the 2001 case disappeared when the plaintiffs’ lawyers withdrew it the same year. In that case, the decision to withdraw came after several German companies that had contributed to a Holocaust victims reparations fund threatened to stop donating unless any and all legal action was off the table. Not wanting to shortchange that fund, the lawyers withdrew the case.
Ultimately, IBM Germany did agree to donate $3 million to that Holocaust fund — with the clear stipulation that the contribution was not an admission of liability.
IBM and the Holocaust, by Edwin Black
This Expanded Edition of the award-winning, New York Times bestselling shocker, offers 37 pages of previous unpublished documents, pictures, internal IBM correspondence, and other archival materials. Originally published to rave reviews in 2001, this provocative volume has stood the test of time. Chronicling the story of Big Blue’s strategic alliance with Nazi Germany, ‘IBM and the Holocaust’ is a chilling investigation into corporate complicity
VII: With Blitzkrieg Efficiency
Hitler’s armies swarmed over Europe throughout the first months of 1940. The forces of the Reich slaughtered all opposition with a military machine unparalleled in human history.
Blitzkrieg — lightning war — was more than a new word. Its very utterance signified coordinated death under the murderous onslaught of Hitler’s massive air, sea, and 100,000-troop ground assaults. Nothing could stop Germany.
Nazi Europe — and Berlin’s new world order — was becoming a reality. Austria: annexed in March 1938. Sudetenland: seized October 1938. Czechoslovakia: dismembered March 1939, and the Memel region ceded from Lithuania that same month. Poland: invaded September 1939. By January 1940, nearly 42 million people had come under brutal German subjugation. Disease, starvation, shattered lives, and fear became the desolate truth across the Continent.
The Jews were running out of refuges. One overrun sanctuary after another slid back into the familiar nightmare of registration, confiscation, and ghettoization
No sooner did the Swastika flag of occupation unfurl, than the anti-Semitic decrees rolled out. Eastern European countries not yet conquered emulated the pattern as German sympathizers and surrogates in Romania, Hungary, and Italy undertook Berlin’s bidding to destroy local Jewish populations.
As the winter receded, the Reich prepared for further aggression. By spring 1940, Nazi Germany began dismembering Scandinavia and the Low Countries. April 9, the Wehrmacht invaded Denmark and Norway. Several days later, tiny Luxembourg was taken. May 15, Germany crushed Holland into complete submission. May 28, Belgium capitulated to German forces. During April and May, Germany’s enslavement jurisdiction grew to 65 million Europeans.
A Dehomag IBM poster, circa 1934. Approximate English translation: “See everything with Hollerith punch cards.” (photo credit: courtesy/Edwin Black Collection)
Cities across Europe smoldered in ruin. Warsaw was pulverized into a shambles. Rotterdam was mercilessly bombed even after its surrender on May 14 because, as Berlin propagandists explained, Dutch officials exceeded the ultimatum deadline by some twenty minutes. An elaborate Nazi newsreel, filmed by parachuting cameramen, showed Rotterdam almost completely aflame. Airports at Brussels and Antwerp were bombed and strafed by hundreds of Luftwaffe planes.
Nazi-commandeered trains crisscrossed the continent hauling into Germany looted coal, scrap metal, foodstuffs, machinery, and the other essentials Berlin craved. When they weren’t carrying raw materials, or transporting troops, the railroad cars freighted conscripted labor en route to work projects as well as expelled Jews destined for concentration camps.
Mass executions, organized plunder, and ruthless invasion — these blared across the front pages of the newspapers, the frames of newsreels, and the broadcasts of radio news. Germany was portrayed in emotional headlines and feature articles as a savage, murderous nation bent on destroying and dominating all of Europe no matter how many people died. On April 2,
Poland’s exile government declared that in addition to a million prisoners and forced laborers transported to German work sites, an estimated 2.5 million had died as a result of military action, executions, starvation, or frigid homelessness. Headlines continued as the New York Times grossly exaggerated the five days of Germany’s invasion of the Netherlands which commenced May 10; the newspaper claimed a quarter of the Dutch army was killed — more than 100,000 (even though the number was 2,200).
Moreover, millions of Jews were now clearly earmarked for death by virtue of Hitler’s oppressive measures. In November 1939, the New York Times published reports from Paris declaring that 1.5 million Jews trapped in Poland were in danger of starving to death. On January 21, 1940, World Jewish Congress Chairman Nahum Goldmann warned a Chicago crowd of 1,000, as well as wire service reporters, that if the war continued for another year 1 million Polish Jews would die of calculated starvation or outright murder. Such dire predictions only capped years of saturation media coverage about inhumane Jewish persecution and horrifying concentration camps.
Indeed, whenever Jewish persecution was reported, the media invariably reported the incessant registrations and censuses as Nazidom’s initial step. The methodology, technology, and the connection to IBM were still far below public awareness. But some specifics were beginning to appear. For example, a March 2, 1940, New York Timesarticle, entitled “Jews in Cracow Move to Ghettos,” described how 80,000 Jews had been herded into overcrowded flats in a squalid urban district devoid of resources. “A common sight,” the report asserted, “is the white armband with the blue Star of David, which all Jews must wear by government decree . . . [signifying] their registration in the government card file.”
Thomas J. Watson, circa 1920s (photo credit: courtesy/ Edwin Black Collection, IBM corporate archives)
Only with great caution could Watson now publicly defend the Hitler agenda, even through euphemisms and code words. Most Americans would not tolerate anyone who even appeared to be a Nazi sympathizer or collaborator. So, as he had done since Kristallnacht in late 1938, Watson continued to insert corporate distance between himself and all involvement in the affairs of his subsidiaries in Nazi Europe — even as he micro-managed their day-to-day operations. More than ever, he now channeled his communications to Nazi Europe through trusted intermediaries in Geneva and elsewhere on the Continent. He controlled subsidiary operations through attorneys and employees acting as nominee owners, following the pattern set in Czechoslovakia and Poland.
In May 1940, as American society prepared for an inevitable war with Hitler, Watson worked to secure the underpinnings of his public image. He intensified his advocacy for peace, and against all war.
“Universal peace is one of the most desirable, most worthwhile ideals in the world today,” Watson insisted in a May 4 speech to reporters. “It cannot be sold by a few people working in widely scattered communities. The project requires a worldwide organization of enthusiastic, hard-working individuals selling the gospel of peace.” Watson advertised IBM as such an organization.
Four days later, on May 8, Watson told reporters that the company’s latest course held in Endicott, New York, for IBM sales representatives from twenty-four countries was to “enable the students . . . to make greater contributions to the cause of world peace through world trade.”
Watson’s advocacy for peace was limitless. May 13, 1940 was proclaimed IBM Day at the World’s Fair being held that month in New York. IBM Day was nothing less than an extravaganza of orchestrated adulation for the company. A dozen chartered trains brought in 7,000 IBM employees and their wives from company facilities across the nation to visit the architectonic IBM Pavilion. Each IBMer wore a red ribbon of solidarity with the company. Two thousand lucky ones were chosen to be feted at a massive Waldorf-Astoria dinner. Special congratulations to IBM, as usual, were issued by leading politicians from President Roosevelt to the Mayor of New York. To underscore the drama, Watson commissioned an original orchestral work, “The IBM Symphony,” a bombastic composition dedicated to the uplifting spirit of the firm.
The climax of IBM Day, however, was Watson’s speech on the subject of peace. He delivered his sermon to 30,000 specially invited guests gathered at the vast Court of Peace located in front of the sweeping USA Pavilion. Mutual Radio broadcast the highly publicized event countrywide.
Even as Watson was preaching the imperatives of peace, IBM was ecstatic about its accomplishments revolutionizing warfare not only for the Third Reich, but also for its Axis allies
Peace was Watson’s message. War was bad, he argued at every opportunity. It would prove nothing but military might, waste lives and precious resources. War was in fact the worst recourse for the world, and all right-thinking men should be opposed to any involvement with it, Watson pleaded. As head of the Carnegie Endowment for International Peace, Watson everywhere proclaimed his driving mantra: “World Peace through World Trade.” Indeed, Watson must have seemed to the public like the very champion of peace and the arch adversary of all conflict. Ironically, at that very moment, Watson and IBM were in fact Europe’s most successful organizers not of peace, but of the ravages of war.
Even as Watson was preaching the imperatives of peace, IBM was ecstatic about its accomplishments revolutionizing warfare not only for the Third Reich, but also for its Axis allies and even other European nations about to be vanquished by Hitler. In spring 1940, J. W. Schotte, IBM’s general manager for Europe, dispatched a confidential report from his Geneva office to senior IBM executives in America. Schotte’s dispatch addressed the activities not only of just Dehomag, but also of the two dozen European subsidiaries and agencies that worked as inter-connected branches of the New York company.
Schotte’s enthusiastic memo was entitled “Our Dealings with War Ministries in Europe.” It began, “Up to about one and a half years ago [about the time of Kristallnacht in 1938], our negotiations with the war ministries of the twenty-four countries which are under the jurisdiction of IBM European headquarters in Geneva, had not been very successful. This was due to several rea sons, but mainly to the fact that in military circles administration was considered a ‘necessary evil’ of little importance for the defense of the country.”
A typical Hitler-era letter from IBM Geneva to IBM NY micromanaging its German subsidiary. There were thousands of such communications during the Reich years. (photo credit: courtesy Edwin Black Collection, IBM files)
IBM had finally succeeded in gaining the necessary insider access to sensitive military projects, Schotte reported, so that company engineers could properly design punch card applications for war use. Schotte explained that in prior years “the military men in Europe have been reluctant to reveal their problems and programs to civilians. It has been overlooked in such instances that there is a distinct difference between knowing which problems exist and what system is applied, and the data and figures to which the system has to be applied.” As such, Schotte drew a fine theoretical distinction between IBM possessing specific knowledge of the facts about a military operation, such as the number of people to be counted or a list of German bombing raids, and the actions themselves.
The big change in military acceptance of Hollerith systems appeared at the end of 1938, confirmed Schotte, when “in Germany a campaign started for, what has been termed . . . ‘organization of the second front.’ ” He elaborated, “In military literature and in newspapers, the importance and necessity of having in all phases of life, behind the front, an organization which would remain intact and would function with ‘Blitzkrieg’ efficiency . . . was brought out. What we had been preaching in vain for years all at once began to be realized.”
Revenues from IBM’s dominant customer, the Third Reich, was growing so rapidly, Schotte said he did not yet possess the sales numbers. ‘We have no details of Germany,’ he reported, ‘but know that a large amount of punched card equipment is being used by the War Ministry’
Schotte’s memo made clear that only at IBM’s initiative did the militarists comprehend what magic they could achieve with Hollerith automation. “Lectures on the punched card system were held by our representatives before officials of the general staff of various countries and, with our men, the study of possible applications was begun . . . progress was rather slow, and it was not until about eight or nine months ago [summer 1939] when conditions in Europe clearly indicated that a war was more or less unavoidable, that the matter became acute.”
Asserting that IBM sold to either side and had enjoyed an ever-escalating volume since the summer of 1939, Schotte’s memo declared, “The War Ministries of Yugoslavia, Rumania, Hungary, Poland, Sweden, Holland and France (these are the ones that I remember very distinctly from memory) sent us orders for punched card equipment, some of which is already installed, others being installed when the war started, and further equipment not yet installed or still in transport.”
Revenues from IBM’s dominant customer, the Third Reich, was growing so rapidly, Schotte said he did not yet possess the sales numbers. “We have no details of Germany,” he reported, “but know that a large amount of punched card equipment is being used by the War Ministry.” He added that so great was Germany’s need in the months before and after the invasion of Poland that the Reich began requisitioning machines. Indeed, the agency ultimately known as the Maschinelles Berichtwesen (MB) had exercised full authority over all punch card technology since 1937. “In the second half of 1939,” wrote Schotte, “most of our equipment was ‘seized’ and used to supplement the installations already in operation.”
Once war erupted, the haste to add machines for military use was not confined to Germany. Schotte’s report noted that “rush orders were placed with us” by those countries not yet properly automated. Most IBM subsidiaries were two years behind in filling orders, so many war ministries hurried their orders just to get in queue. “To make up for lost time,” Schotte continued, “Holland and France gave us blank orders for a large quantity of machines, although our studies were not completed for several of the uses, and the quantities of required machines not established. As late as February 1940, the French War Ministry ordered a very substantial quantity of machines.”
Schotte’s report clarified that not all war applications were handled directly by war ministries. Numerous systems had been conveyed to private industry, “but are for their [war ministry] use and under their control.” Therefore, even though a coal mine or insurance company might be listed as the account, utilization of the machines was dictated by military needs either on the original corporate premises or moved to a more secure location altogether. Indeed, by spring 1940, his memo confirmed, many such systems had already been relocated to more protected sites, the report acknowledged.
So comprehensive was IBM Europe’s data on both Germany and its enemies that Schotte’s memo was able to assert that the punch cards maintained ‘records of each and every Communist and Nazi’
Widespread expansion of punch card systems for war was ironically undermined in various countries by the draft itself, which infringed on the punch card workforce, asserted Schotte. However, eventually, military officials exempted “key men in our installations [who then] remained at their posts.” Moreover, “supervisors and our indispensable servicemen were released for such work.” Even still, he added, “A great inconvenience was caused due to the sudden extension of equipment in most countries, a shortage of trained supervisors and punch operators. Ads were placed in the papers and such operators lured away from one installation to another by offering higher salaries. We hurriedly started training schools for key punch operators and supervisors, and of course servicemen who would be exempted from military service due to age or physical condition.”
Europe’s militarists had finally realized the indispensable advantages Hollerith instilled into modern warfare, boasted Schotte. Punch cards freed up manpower. Schotte cited a typical case: “For example, in Hungary with one set of machines and a few operators we replaced about sixty men.” He added that the machines “work twenty-four hours without vacation. The place and location is immaterial, and machines have been installed in bombproof cellars. . . . There is no limit to the flexibility and adaptability of the machines, provided the mass of data to be handled is sufficiently large.”
Most importantly, stressed Schotte, Hollerith machines guaranteed “speed in handling mass records and data. Such speed would be absolutely impossible by manual methods,” he stressed.
Schotte’s report included a list of IBM’s remarkable accomplishments for the armies of war-ravaged Europe. Personal information about every officer and soldier resided on Hollerith systems. In France, for example, the actual “mobilization call to each officer was printed by our equipment by means of punch cards.” Hollerith machines controlled all payrolls to both armies and civilian workers in munitions factories.
So comprehensive was IBM Europe’s data on both Germany and its enemies that Schotte’s memo was able to assert that the punch cards maintained “records of each and every Communist and Nazi.”
Beyond Nazi War Crimes Experiments: The Voluntary Consent Requirement of the Nuremberg Code at 70
See „Marking the 70th Anniversary of the Doctors’ Trial at Nuremberg“ in volume 108 on page 12.
See „From Nuremberg to Guantanamo Bay: Uses of Physicians in the War on Terror“ in volume 108 on page 36.
See „American Doctors at the Nuremberg Medical Trial“ in volume 108 on page 47.
See „The Nazi Physicians as Leaders in Eugenics and “Euthanasia”: Lessons for Today“ in volume 108 on page 53.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719679/
Gene Editing and the New Eugenics
Medical inventor and author David Martin proves that the Pfiser and Moderna mRNA vaccines are not vaccines by medical definition and how Big Pharma is using national and state emergency authorizations to force these untested gene therapies onto the population.
David E. Martin Speaker, Author, Fully Human
‘Butterfly’ of the Week: Hidden in Plain Sight…
References
• It is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product or service can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made.
• Definition of Vaccine https://www.cdc.gov/vaccines/vac-gen/imz-basics.htm
• Immunity: Protection from an infectious disease. If you are immune to a disease, you can be exposed to it without becoming infected.
• Vaccine: A product that stimulates a person’s immune system to produce immunity to a specific disease, protecting the person from that
disease. Vaccines are usually administered through needle injections, but can also be administered by mouth or sprayed into the nose.
• “The primary endpoint is the prevention of symptomatic COVID-19 disease. Key secondary endpoints include prevention of severe COVID- 19 disease and prevention of infection by SARS-CoV-2.” https://web.archive.org/web/20210313113005/https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy/#:%7E:text=About%20the%20Phase%203%20COVE%20Study&text=The%20primary%20endpoint%20is%20the,by%20SARS%2DCoV%2D2.
• “As of this writing, no correlate of protection for SARS-CoV-2 has been established.” https://www.nejm.org/doi/full/10.1056/NEJMoa2028436
• “No existing vaccines have been shown to be effective against infection with any betacoronavirus, the family that includes SARS-CoV-2, which causes Covid-19.” Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-2615.
A New Frontier: Integrating Behavioral and Digital Technology to Promote Health Behavior
Behav Anal. 2015 May; 38(1): 19–49.
Published online 2014 Aug 23. doi: 10.1007/s40614-014-0017-y
PMCID: PMC4883489
NIHMSID: NIHMS767697
PMID: 27347477
Cleveland Clinic and IBM Unveil Landmark 10-Year Partnership to Accelerate Discovery in Healthcare and Life Sciences
IBM Hybrid Cloud, High Performance Computing, Artificial Intelligence, and Quantum Computing technologies to serve as foundation for newly launched Cleveland Clinic Global Center for Pathogen Research & Human Health
IBM plans to install its first private-sector, on premises quantum computing system in the U.S. at Cleveland Clinic. Cleveland Clinic also plans to receive first, next-generation IBM 1,000+ qubit quantum system in the coming years
Mar 30, 2021
ARMONK, N.Y. and CLEVELAND, March 30, 2021/PRNewswire/ — Cleveland Clinic and IBM (NYSE: IBM) have announced a planned 10-year partnership to establish the Discovery Accelerator, a joint Cleveland Clinic – IBM center with the mission of fundamentally advancing the pace of discovery in healthcare and life sciences through the use of high performance computing on the hybrid cloud, artificial intelligence (AI) and quantum computing technologies.
The collaboration is anticipated to build a robust research and clinical infrastructure to empower big data medical research in ethical, privacy preserving ways, discoveries for patient care and novel approaches to public health threats such as the COVID-19 pandemic. Through the Discovery Accelerator, the researchers plan to use advanced computational technology to generate and analyze data to help enhance research in the new Global Center for Pathogen Research & Human Health, in areas such as: genomics, single cell transcriptomics, population health, clinical applications, and chemical and drug discovery.
As part of the collaboration, IBM plans to install its first private sector, on-premises IBM Quantum System One in the United States, to be located on Cleveland Clinic’s campus in Cleveland. The company also plans to install the first of IBM’s next-generation 1,000+ qubit quantum systems at a client facility, also to be located in Cleveland, in the coming years. This quantum program will be designed to actively engage with universities, government, industry, startups and other relevant organizations. It will leverage Cleveland Clinic’s global enterprise to serve as the foundation of a new quantum ecosystem for life sciences, focused on advancing quantum skills and the mission of the center.
„Through this innovative collaboration, we have a unique opportunity to bring the future to life,“ said Tom Mihaljevic, M.D., CEO and President of Cleveland Clinic. „These new computing technologies can help revolutionize discovery in the life sciences. The Discovery Accelerator will enable our renowned teams to build a forward-looking digital infrastructure and help transform medicine, while training the workforce of the future and potentially growing our economy.“
„The COVID-19 pandemic has spawned one of the greatest races in the history of scientific discovery – one that demands unprecedented agility and speed,“ said Arvind Krishna, Chairman and Chief Executive Officer of IBM. „At the same time, science is experiencing a change of its own – with high performance computing, hybrid cloud, data, AI, and quantum computing, being used in new ways to break through long-standing bottlenecks in scientific discovery. Our new collaboration with Cleveland Clinic will combine their world-renowned expertise in healthcare and life sciences with IBM’s next-generation technologies to make scientific discovery faster, and the scope of that discovery larger than ever.“
„Quantum will make the impossible possible, and when the Governor and I announced the Cleveland Innovation District earlier this year, this was the kind of innovative investment I hoped it would advance,“ said Ohio Lt. Governor Jon Husted, Director of InnovateOhio. „A partnership between these two great institutions will put Cleveland, and Ohio, on the map for advanced medical and scientific research, providing a unique opportunity to improve treatment options for patients and solve some of our greatest healthcare challenges.“
The Discovery Accelerator will serve as the technology foundation for Cleveland Clinic’s new Global Center for Pathogen Research & Human Health, announced last month as part of the Cleveland Innovation District. The center, supported by a $500 million investment from the State of Ohio, Jobs Ohio and Cleveland Clinic, brings together a research team focused on broadening understanding of viral pathogens, virus-induced cancers, gvenomics, immunology and immunotherapies. It will build upon Cleveland Clinic’s existing programs and expertise, with newly recruited world leaders in immunology, cancer biology, immune-oncology and infectious disease research as well as technology development and education. Researchers will expand critical work on studying, preparing and protecting against emerging pathogens and virus-related diseases.
Accelerating Discovery
The pace of progress in science historically has been limited by bottlenecks. Researchers are increasingly working to overcome these bottlenecks with the application of AI, quantum computing and hybrid cloud technologies. New technologies are enabling accelerated methods of discovery that include deep search, AI and quantum-enriched simulation, generative models, and cloud-based AI-driven autonomous labs. Leveraging these combined innovations will supercharge new generations of information technology, fuel important advances in science, and IBM will provide access to a variety of research and commercial technologies, education and tools to assist Cleveland Clinic in accelerating discovery in healthcare and life science, including RoboRXN, a cloud-based platform that combines AI models and robots to help scientists design and synthesize new molecules remotely; the IBM Functional Genomics Platform, a cloud-based repository and research tool, which uses novel approaches to reveal the molecular features in viral and bacterial genomes to help accelerate discovery of molecular targets required for drug design, test development and treatment; Deep Search, which helps researchers access structured and unstructured data quickly; and High-Performance Hybrid Cloud Computing technologies that can enable researchers to „burst“ their workloads into the cloud and access the resources they need at scale.
IBM Quantum Flagship Program
Quantum computing has the potential to have an immense impact on key healthcare challenges, such as the discovery of new molecules that can serve as the basis of new pharmaceutical breakthroughs and spur the development of new medicines and could help enhance the ability to derive deep insight from complex data that is at the heart of some of the largest challenges in healthcare.
The Discovery Accelerator will leverage IBM’s multi-year roadmap for advancing quantum computing, bringing its revolutionary capabilities into the hands of scientists and practitioners in healthcare and life sciences. In addition to an on-premises quantum system, Cleveland Clinic will also have access to IBM’s fleet of currently more than 20 quantum systems, accessible via the cloud. IBM is targeting to unveil its first next generation 1,000+ qubit quantum system in 2023, and Cleveland Clinic is planned to be the site of the first private-sector on-premises system.
Building Quantum Skills in Ohio
A significant pillar of the program plans to focus on educating the workforce of the future and creating jobs to grow the economy. The 10-year collaboration plans to include education and workforce development opportunities related to quantum computing.
The innovative educational curriculum will be designed for participants from high school to professional level and offer training and certification programs in data science and quantum computing, building the skilled workforce needed for cutting-edge data science research of the future. Cleveland Clinic and IBM plan to hold research symposia and workshops with joint sessions by IBM and academic researchers for academia, industry, government and the general public.
About Cleveland Clinic
Cleveland Clinic – now in its centennial year – is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S. News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual „America’s Best Hospitals“ survey. Among Cleveland Clinic’s 70,800 employees worldwide are more than 4,660 salaried physicians and researchers, and 18,500 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,500-bed health system that includes a 173-acre main campus near downtown Cleveland, 19 hospitals, more than 220 outpatient facilities, and locations in southeast Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2020, there were 8.7 million total outpatient visits, 273,000 hospital admissions and observations, and 217,000 surgical cases throughout Cleveland Clinic’s health system. Patients came for treatment from every state and 185 countries. Visit us at clevelandclinic.org. Follow us at twitter.com/ClevelandClinic. News and resources available at newsroom.clevelandclinic.org.
About IBM
For more information about IBM, visit https://www.ibm.com/
Statements regarding IBM’s future direction and intent are subject to change or withdrawal without notice and represent goals and objectives only.
Cleveland Clinic and IBM Unveil First Quantum Computer Dedicated to Healthcare Research
IBM Quantum System One deployed at Cleveland Clinic as part of landmark 10-year partnership
Mar 20, 2023
CLEVELAND and ARMONK, N.Y., March 20, 2023/PRNewswire/ — Today, Cleveland Clinic and IBM (NYSE: IBM) officially unveiled the first deployment of an onsite private sector IBM-managed quantum computer in the United States. The IBM Quantum System One installed at Cleveland Clinic will be the first quantum computer in the world to be uniquely dedicated to healthcare research with an aim to help Cleveland Clinic accelerate biomedical discoveries.
Ruoyi Zhou, Director, The IBM Discovery Accelerator at the Cleveland Clinic, Dr. Lara Jehi, Chief Research Information Officer, Cleveland Clinic, Congresswoman Shontel Brown (OH-11), Dario Gil, IBM SVP and Director, Research, Gary Cohn, IBM Vice Chairman, Lt. Governor of Ohio Jon Husted, Dr. Serpil Erzurum, Chief Research and Academic Officer, Cleveland Clinic, Susan Monarez, Ph.D., Deputy Director, Advanced Research Projects Agency for Health (ARPA-H), Tom Mihaljevic, M.D., Cleveland Clinic CEO and President, and Mayor of Cleveland Justin M. Bibb, in front of IBM Quantum System One at Cleveland Clinic Main Campus
Quantum computing is a rapidly emerging technology that harnesses the laws of quantum mechanics to solve problems that today’s most powerful supercomputers cannot practically solve. The ability to tap into these new computational spaces could help researchers identify new medicines and treatments more quickly.
„This is a pivotal milestone in our innovative partnership with IBM, as we explore new ways to apply the power of quantum computing to healthcare,“ said Tom Mihaljevic, M.D., Cleveland Clinic CEO and President and Morton L. Mandel CEO Chair. „This technology holds tremendous promise in revolutionizing healthcare and expediting progress toward new cares, cures and solutions for patients. Quantum and other advanced computing technologies will help researchers tackle historic scientific bottlenecks and potentially find new treatments for patients with diseases like cancer, Alzheimer’s and diabetes.“
„With the unveiling of IBM Quantum System One at Cleveland Clinic, their team of world-class researchers can now explore and uncover new scientific advancements in biomedical research,“ said Arvind Krishna, IBM Chairman and CEO. „By combining the power of quantum computing, artificial intelligence and other next-generation technologies with Cleveland Clinic’s world-renowned leadership in healthcare and life sciences, we hope to ignite a new era of accelerated discovery.“
In addition to quantum computing, the Cleveland Clinic-IBM Discovery Accelerator draws upon a variety of IBM’s latest advancements in computing technologies, including high performance computing via the hybrid cloud and artificial intelligence. Researchers from both organizations are collaborating closely on a robust portfolio of projects with these advanced technologies to generate and analyze massive amounts of data to enhance research.
The Cleveland Clinic-IBM Discovery Accelerator has generated multiple projects that leverage the latest in quantum computing, AI and hybrid cloud to help expedite discoveries in biomedical research. These include:
- Development of quantum computing pipelines to screen and optimize drugs targeted to specific proteins;
- Improvement of a quantum-enhanced prediction model for cardiovascular risk following non-cardiac surgery; and
- Application of artificial intelligence to search genome sequencing findings and large drug-target databases to find effective, existing drugs that could help patients with Alzheimer’s and other diseases.
The Discovery Accelerator also serves as the technology foundation for Cleveland Clinic’s Global Center for Pathogen & Human Health Research, part of the Cleveland Innovation District. The center, supported by a $500 million investment from the State of Ohio, Jobs Ohio and Cleveland Clinic, brings together a team focused on studying, preparing and protecting against emerging pathogens and virus-related diseases. Through the Discovery Accelerator, researchers are leveraging advanced computational technology to expedite critical research into treatments and vaccines.
A significant part of the collaboration is a focus on educating the workforce of the future and creating jobs to grow the economy. An innovative educational curriculum is being designed for participants from high school to the professional level, offering training and certification programs in data science, machine learning and quantum computing to build the skilled workforce needed for cutting-edge computational research of the future.
Additionally, the two organizations are hosting research symposia, seminars and workshops intended for academia, industry, government and the public with a goal of building a critical mass of computing specialists in Cleveland.
About Cleveland Clinic
Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S. News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual „America’s Best Hospitals“ survey. Among Cleveland Clinic’s 77,000 employees worldwide are more than 5,658 salaried physicians and researchers, and 19,000 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,665-bed health system that includes a 173-acre main campus near downtown Cleveland, 22 hospitals, more than 275 outpatient facilities, including locations in northeast Ohio; southeast Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2022, there were 12.8 million outpatient encounters, 303,000 hospital admissions and observations, and 270,000 surgeries and procedures throughout Cleveland Clinic’s health system. Patients came for treatment from every state and 185 countries.
Visit us at clevelandclinic.org. Follow us at twitter.com/ClevelandClinic. News and resources available at newsroom.clevelandclinic.org.
About IBM
IBM is a leading global hybrid cloud and AI, and business services provider, helping clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,800 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service. For more information, visit https://research.ibm.com.
Contacts:
Sarah Benchaita
IBM Research
281-455-6432
Sarah.benchaita@ibm.com
Alicia Reale
Cleveland Clinic
216-408-7444
Realeca@ccf.org
Ellie Westerburg
Cleveland Clinic
216-312-4755
westere@ccf.org
SOURCE IBM
- IBM Cleveland Clinic Unveil Quantum Computer
- IBM & Cleveland Clinic Unveils Quantum Computer Group Photo
Operation Warp Speed:Accelerated COVID-19 Vaccine Development Status and Efforts to Address Manufacturing Challenges
GAO-21-319Published: Feb 11, 2021. Publicly Released: Feb 11, 2021.
https://www.gao.gov/products/gao-21-319
What GAO Found
Operation Warp Speed (OWS)—a partnership between the Departments of Health and Human Services (HHS) and Defense (DOD)—aimed to help accelerate the development of a COVID-19 vaccine. GAO found that OWS and vaccine companies adopted several strategies to accelerate vaccine development and mitigate risk. For example, OWS selected vaccine candidates that use different mechanisms to stimulate an immune response (i.e., platform technologies; see figure). Vaccine companies also took steps, such as starting large-scale manufacturing during clinical trials and combining clinical trial phases or running them concurrently. Clinical trials gather data on safety and efficacy, with more participants in each successive phase (e.g., phase 3 has more participants than phase 2).
Vaccine Platform Technologies Supported by Operation Warp Speed, as of January 2021
As of January 30, 2021, five of the six OWS vaccine candidates have entered phase 3 clinical trials, two of which—Moderna’s and Pfizer/BioNTech’s vaccines—have received an emergency use authorization (EUA) from the Food and Drug Administration (FDA). For vaccines that received EUA, additional data on vaccine effectiveness will be generated from further follow-up of participants in clinical trials already underway before the EUA was issued.
Technology readiness. GAO’s analysis of the OWS vaccine candidates‘ technology readiness levels (TRL)—an indicator of technology maturity— showed that COVID-19 vaccine development under OWS generally followed traditional practices, with some adaptations. FDA issued specific guidance that identified ways that vaccine development may be accelerated during the pandemic. Vaccine companies told GAO that the primary difference from a non-pandemic environment was the compressed timelines. To meet OWS timelines, some vaccine companies relied on data from other vaccines using the same platforms, where available, or conducted certain animal studies at the same time as clinical trials. However, as is done in a non-pandemic environment, all vaccine companies gathered initial safety and antibody response data with a small number of participants before proceeding into large-scale human studies (e.g., phase 3 clinical trials). The two EUAs issued in December 2020 were based on analyses of clinical trial participants and showed about 95 percent efficacy for each vaccine. These analyses included assessments of efficacy after individuals were given two doses of vaccine and after they were monitored for about 2 months for adverse events.
Manufacturing. As of January 2021, five of the six OWS vaccine companies had started commercial scale manufacturing. OWS officials reported that as of January 31, 2021, companies had released 63.7 million doses—about 32 percent of the 200 million doses that, according to OWS, companies with EUAs have been contracted to provide by March 31, 2021. Vaccine companies face a number of challenges in scaling up manufacturing to produce hundreds of millions of doses under OWS’s accelerated timelines. DOD and HHS are working with vaccine companies to help mitigate manufacturing challenges, including:
- Limited manufacturing capacity: A shortage of facilities with capacity to handle the vaccine manufacturing needs can lead to production bottlenecks. Vaccine companies are working in partnership with OWS to expand production capacity. For example, one vaccine company told GAO that HHS’s Biomedical Advanced Research and Development Authority helped them identify an additional manufacturing partner to increase production. Additionally, the U.S. Army Corps of Engineers is overseeing construction projects to expand capacity at vaccine manufacturing facilities.
- Disruptions to manufacturing supply chains: Vaccine manufacturing supply chains have been strained by the global demand for certain goods and workforce disruptions caused by the global pandemic. For example, representatives from one facility manufacturing COVID-19 vaccines stated that they experienced challenges obtaining materials, including reagents and certain chemicals. They also said that due to global demand, they waited 4 to 12 weeks for items that before the pandemic were typically available for shipment within one week. Vaccine companies and DOD and HHS officials told GAO they have undertaken several efforts to address possible manufacturing disruptions and mitigate supply chain challenges. These efforts include federal assistance to (1) expedite procurement and delivery of critical manufacturing equipment, (2) develop a list of critical supplies that are common across the six OWS vaccine candidates, and (3) expedite the delivery of necessary equipment and goods coming into the United States. Additionally, DOD and HHS officials said that as of December 2020 they had placed prioritized ratings on 18 supply contracts for vaccine companies under the Defense Production Act, which allows federal agencies with delegated authority to require contractors to prioritize those contracts for supplies needed for vaccine production.
- Gaps in the available workforce: Hiring and training personnel with the specialized skills needed to run vaccine manufacturing processes can be challenging. OWS officials stated that they have worked with the Department of State to expedite visa approval for key technical personnel, including technicians and engineers to assist with installing, testing, and certifying critical equipment manufactured overseas. OWS officials also stated that they requested that 16 DOD personnel be detailed to serve as quality control staff at two vaccine manufacturing sites until the organizations can hire the required personnel.
Why GAO Did This Study
As of February 5, 2021, the U.S. had over 26 million cumulative reported cases of COVID-19 and about 449,020 reported deaths, according to the Centers for Disease Control and Prevention. The country also continues to experience serious economic repercussions, with the unemployment rate and number of unemployed in January 2021 at nearly twice their pre-pandemic levels in February 2020. In May 2020, OWS was launched and included a goal of producing 300 million doses of safe and effective COVID-19 vaccines with initial doses available by January 2021. Although FDA has authorized two vaccines for emergency use, OWS has not yet met its production goal. Such vaccines are crucial to mitigate the public health and economic impacts of the pandemic.
GAO was asked to review OWS vaccine development efforts. This report examines: (1) the characteristics and status of the OWS vaccines, (2) how developmental processes have been adapted to meet OWS timelines, and (3) the challenges that companies have faced with scaling up manufacturing and the steps they are taking to address those challenges.
GAO administered a questionnaire based on HHS’s medical countermeasures TRL criteria to the six OWS vaccine companies to evaluate the COVID-19 vaccine development processes. GAO also collected and reviewed supporting documentation on vaccine development and conducted interviews with representatives from each of the companies on vaccine development and manufacturing.
For more information, contact Karen L. Howard and Candice N. Wright at (202) 512-6888 or howardk@gao.govor wrightc@gao.gov.
Strengthening Multilateral Diplomacy and Sustainable Development
4,000 Patents: Why the ‘Novel’ SARS-CoV-2 Virus Isn’t so Novel
WHO Regulation and Prequalification
DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH
The Role of the National Institute of Allergy and Infectious Diseases in Research on Influenza Vaccine Innovation
Testimony before the House Committee on Science, Space, and Technology
Anthony S. Fauci, M.D.
Director National Institute of Allergy and Infectious Diseases National Institutes of Health
November 20, 2019
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-3619
What were the major sources of funding for clinical trials focused on the development of therapeutics and vaccines against COVID-19 between January 1, 2020, and August 31, 2021? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382437/
MODERNA 10-K
https://content.edgar-online.com/ExternalLink/EDGAR/0001682852-20-000006.html?hash=482511f28a1183149d8e2a92bfe5692cfcf227dcde5c5cf840adb4f672b76cfc&dest=MODERNA10-K12312019_HTM#MODERNA10-K12312019_HTM
Financial report Pfizer 2019
https://www.sec.gov/Archives/edgar/data/78003/000007800320000014/pfe-exhibit13x12312019.htm
https://www.nasdaq.com/press-release/pfizer-provides-full-year-2024-guidance-2023-12-13
A further description of these and other risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. See also the Overview of Our Performance, Operating Environment, Strategy and Outlook — Our 2022 Performance and — The Global Economic Environment sections of Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) in Pfizer’s 2022 Annual Report on Form 10-K; and the Overview of Our Performance, Operating Environment, Strategy and Outlook — Our Third Quarter 2023 and First Nine Months of 2023 Performance and — The Global Economic Environment sections of MD&A in Pfizer’s Quarterly Report on Form 10-Q for the quarterly period ended October 1, 2023 (available at www.pfizer.com).
Category: Financial
View source version on businesswire.com: https://www.businesswire.com/news/home/20231213173781/en/
Do you Know that Bill Gates parents work for IBM and planned Parenthood?
Jeffrey Epstein’s Links To Scientists Are Even More Extensive Than We Thought
Scientists took Epstein’s money or associated with the financier after he was jailed for soliciting an underage girl for prostitution. Some say they are sorry. Others didn’t comment.
Read for yourself: https://www.buzzfeednews.com/article/peteraldhous/jeffrey-epstein-science-donations-apologies-statements
Building Better Agriculture One Atom at a Time
Through its 50-year partnership with the Food and Agriculture Organization of the United Nations (FAO), the IAEA works through the Joint FAO/IAEA Division of Nuclear Techniques in Food and Agriculture to support the safe and appropriate use of nuclear technologies in food and agriculture, with the aim of contributing to global food security and sustainable agricultural development. 4 September 2015
This is the pathetic plan for the „Healthy and Sustainable Future“
13. Okt. 2021To achieve vaccine equity, we need to do two things: change how the world allocates doses and increase the amount of vaccine doses being produced in… https://edition.cnn.com/2021/10/13/opinions/closing-vaccine-gap-faster-bill-gates/index.html
Bill Gates: How we can close the vaccine gap much faster next time
BILL GATES BANNED VIDEO: „WE’RE INJECTING GENETICALLY MODIFIED ORGANISM’S INTO LITTLE KIDS ARMS“
At the beginning of the video, Bill Gates tells us how they plan to inject our children with Genetically Modified Organisms. At 14:07 in the video, Bill and Melinda Gates seem to gleefully imagine the next, more deadly pandemic and its effect on people’s attitudes towards their solutions.
Why was this video banned from YouTube?
Since the appearance of COVID-19 last year, we have been in a mad rush to develop a vaccine (forgoing typical safety trials) for a virus that turns out to have a 99.7% recovery rate. Why?
The World Health Organization warns that even after being vaccinated we will still need to wear masks. And, by the way, the vaccine may not prevent the further spread of the virus. Ok wait a minute, but we are believed vaccines do so because thats the whole point of a vaccine?
Not anymore now vaccines has changed thair claim and are now by definition for the prevention from death and bad outcomes in hospitalization.
That means that they’re knew from the beginning that Herdimmunity is never possible!
And just 0,01 % of the natural infected people are harmed by the virus.
Data suggests that Risk and illnesses are increased after the vaccine-roleout.
So why Bill Gates and other Stakeholder are so fanatic pushed to vaccinate the world with an experimental vaccine that may not even stop the spread of this virus? A vaccine, that „corporate media“ has told us has recorded 50 times the adverse reactions of the seasonal influenza vaccine. A virus that, „corporate media“ has told us, seems to have mutated twice already. This makes no sense at all!
With the preliminary adverse events being reported, by independent media, the vaccine has turn out to be more dangerous than the virus itself. And why aren’t we told that Bill Gates is a „VACCINE INVESTOR“ and NOT the „corporate media“ narrative that he’s a philanthropist who just loves humanity?
Bill Gates
Who is behind this heavily promoted campaign to vaccinate the entire world population? One of the most visible proponents is Bill Gates. Aside from being heavily invested in the vaccine industry and the World Health Organization, (and many other global initiatives that promote vaccines) how exactly is Bill Gates qualified to influence public health policy?
He is not an immunologist or even an elected official, yet for some reason, we look to him when setting public health policies. Bill Gates’s lengthy track record with mass vaccination campaigns in other countries has been disastrous, yet we still take his advice. Why!?
Did you know that there are lawmakers in the Italian government that believe Gates should be investigated for crimes against humanity and think his vaccination campaign is used as a depopulation program? Gates seems to be obsessed with global population levels and even stated in a well known Ted Talk that vaccines could be used to reduce the population. Really?
The excuse that Gates gave for such a comment is that by vaccinating, more children will live so parents will not need to have as many children to take care of them in their elder years. Does that answer make sense to you?
Many believe that Gates is actually part of an eugenics movement disguised as healthcare for underdeveloped countries. It is no secret that his family has ties with the eugenics movement of the 20th century. In fact, his father was very involved with Planned Parenthood, an organization which many believe is nothing more than an eugenics program.
The founder of Planned Parenthood, Margeret Sanger was a known casteist steeped in eugenics. Maybe this why almost 80% of all Planned Parenthood facilities are located within walking distance to the African American and Latino communities. If you do a little research on Margeret Sanger and Bill Gates Senior (don’t use Google, use Ecosia) you will find much more on this topic.
Did you know that the Kenyan Catholic Doctors Association found anti-fertility agents in WHO vaccines administered in Africa? They took samples from all over the country and had them independently tested. Every one of the samples came back positive for the anti-fertility agent. This may seem unbelievable but it’s not like we haven’t used sterilization in the past.
Gates and his globalist agenda is not very popular in many other parts of the world either. Robert Kennedy Jr. wrote an article detailing all the damage that was done in developing countries around the world by Bill Gates and the organizations he heavily sponsors.
Die Grüne Revolution
Factsheet – The IMF and the Sustainable Development Goals https://www.imf.org/en/About/Factsheets/Sheets/2016/08/01/16/46/Sustainable-Development-Goals
We must innovate out of COVID to reach the 2030 global goals | World Economic Forum https://www.weforum.org/agenda/2021/03/harness-pace-of-innovation-during-pandemic-to-meet-sdgs/
World Bank Group and The 2030 Agenda https://www.worldbank.org/en/programs/sdgs-2030-agenda
WEF, the United Nations and SDGs https://www.wef.org/advocacy/global-programs/wef-the-united-nations-and-sdgs/
Und ein kleiner Ausblick wie sich die Führungsklasse die Zukunft so vorstellt
Are you ready for Brain Transparency?
No, but here we go!
So who really benefits from the renunciation of everyone and can it perhaps be that this sudden change of heart of the super rich and the political subject to their politics has a completely different goal in mind if they want to encourage us to voluntarily renounce our prosperity, our fundamental rights and our freedom?
The dignity of human..,
The Truth About COVID-19’s Deadliness:
Covid-19: Researchers face wait for patient level data from Pfizer and Moderna vaccine trials
KEI COVID-19 Contract Files Obtained via FOIA with URLs – Google Drive
Federal Agency Name – Defense Advanced Research Projects Agency (DARPA), Biological Technologies Office
Funding Opportunity Title – PREventing EMerging Pathogenic Threats
Funding Opportunity Number – HR001118S0017
We need Courageous and Humanity
And it will happened again and again…
In the sense of truth and justice.
Because without truth
There can be no justice!
ACTIVATE NUREMBERG 2.0!
–
Count 1: 18 U.S.C. § 2331 §§ 802 – Acts of Domestic Terrorism resulting in death of American Citizens
Count 2: 18 USC $ 2339- Conspiring to Commit Acts of Terrorism
Count 3. 15 U.S.C. $1-3 – Conspiring to criminal commercial activity
Count 4. 18 USC $ 175 – Funding and Creating a Biological Weapon
Count 5. 15 U.S.C. §8 – Market manipulation and allocation
Count 6. 18 U.S.C. § 1001 – Lying to Congress
Count 7. 15 U.S.C. § 19 – Interlocking directorates
Count 8. 18 U.S. Code § 2384 – Seditious conspiracy
–
Supreme Court Action
https://youtu.be/8s3EUksu2Fw
–
Attorney General Document
https://www.fullyliveacademy.com/attorneygeneraldocument
–
GATES, FAUCI, AND DASZAK CHARGED WITH GENOCIDE IN INTERNATIONAL COURT FILING t.me/drue86/12500
https://www.fullyliveacademy.com/attorneygeneraldocument
All wars are Banker wars!
And they are always on multiple side’s …
Niemand hat die Absicht eine Mauer zu errichten!
No one intends to build a wall!
Walter Ulbricht in 1961
When Ulbricht said in 1961: „Nobody intends to build a wall“, is there any truth to the idea that he was being deliberately Machiavellian, knowing that most East Germans would read the signs correctly and interpret this as „We intend to build a wall“, then reasoning that if they intended to flee it was now or never, which lead to a surge in numbers which gave Ulbricht the justification he needed to get Khrushchev to authorize it?
I guess if he’d just said „we’re going to build a wall“ it would have caused mass panic and a possible GDR collapse“, but saying it slyly with plausible deniability, before the wall actually went up, gave him the surge in defections he needed to bring things to a head, also getting rid of potential future sources of trouble before the trap closed.
…or was it just a straight up lie…
Respect Me&You & PlanetBlue 🕊
JULIMINATION 
Hinterlasse einen Kommentar